Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.g1therapeutics.com
G1 Therapeutics, Inc. News Releases
Get the latest updates from G1 Therapeutics, Inc. News Releases directly as they happen.
Follow now 60 followers
Latest posts
Last updated 8 months ago
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
8 months ago
- Transaction Will Maximize the Access and Uptake of COSELA ® (trilaciclib)...
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
8 months ago
HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C. , Sept. 05, 2024 (GLOBE...
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
9 months ago
- Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction...
Pharmacosmos Group to Acquire G1 Therapeutics
9 months ago
- Business Combination Expected to Provide Patients with Extensive Stage Small Cell...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9 months ago
RESEARCH TRIANGLE PARK, N.C. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- G1...
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
10 months ago
RESEARCH TRIANGLE PARK, N.C. , July 25, 2024 (GLOBE NEWSWIRE) -- G1...
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
10 months ago
RESEARCH TRIANGLE PARK, N.C. , July 01, 2024 (GLOBE NEWSWIRE) -- G1...
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
11 months ago
- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 months ago
RESEARCH TRIANGLE PARK, N.C. , June 05, 2024 (GLOBE NEWSWIRE) -- G1...
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
12 months ago
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer...
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
12 months ago
RESEARCH TRIANGLE PARK, N.C. , May 23, 2024 (GLOBE NEWSWIRE) -- G1...
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
12 months ago
RESEARCH TRIANGLE PARK, N.C. , May 22, 2024 (GLOBE NEWSWIRE) -- G1...